Week of June 29, 2026 — curated from leading sleep research and health sources, summarized by AI.
ABM was acquired by Cadence Health Capital last month. A new leadership team at the neurology-forward sleep company plans to streamline operations and expand the clinical reach of validated technologies for sleep apnea, insomnia, and neurodegenerative disease.
The oral wellness system features distinct morning and nighttime formulas with ingredients like magnesium and L-theanine. Should it be incorporated into the bedtime routine?
A post hoc analysis of the SELECT trial suggests that semaglutide 2.4 mg is associated with a significantly lower incidence of obstructive sleep apnea in adults with overweight or obesity and established cardiovascular disease. While these findings are promising, Novo Nordisk notes that semaglutide is not currently approved to treat obstructive sleep apnea and further research is required.
'These findings help us better understand the biological mechanisms linking obstructive sleep apnea to metabolic disease.'
A personal story explores why women with cardiovascular disease deserve earlier conversations about sleep-disordered breathing.
Eli Lilly and Company has completed its acquisition of Centessa Pharmaceuticals, securing a portfolio of clinical-stage orexin receptor 2 agonists. This strategic move aims to accelerate the development of new treatments for narcolepsy and other sleep-wake disorders.
Survey findings suggest fatigue remains widespread and debilitating across narcolepsy and idiopathic hypersomnia, even among patients taking medications.
The agency cited the manufacturer for distributing new sleep sack sizes and a clinical bassinet bundle without required clearance, alongside quality system and reporting violations.
A new study reveals that a new barrier has overtaken stress as the primary barrier to sleep for Gen Z.
The late-stage pharmaceutical company announces a leadership transition as it prepares for the potential commercialization of its once-daily oral therapy for obstructive sleep apnea.
The American Academy of Sleep Medicine installs its new board of directors president to lead advocacy and clinical practice initiatives for its 9,500 members.
The National Sleep Foundation conducts a 10-year review of 133 meta-analyses for insights into whether the science has evolved.